Skip to main content
Equibles
CSTL logo

CSTL · Castle Biosciences Inc · Webcasts, Transcripts & Audio

Track CSTL — free

Use CSTL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CSTL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$36.25 +1.74 (+5.03%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.05B
Shares
30.55M
Volume · Oct 28 177.76K Avg daily vol (3M) 397.34K

Castle Biosciences Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Castle Biosciences Inc (CSTL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Castle Biosciences Inc (CSTL) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-15
Castle Biosciences Inc (CSTL) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-12
Castle Biosciences Inc (CSTL) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-30
Castle Biosciences Inc (CSTL) Q2 2026 Earnings Call Transcript
Confident tone TissueCypher volume growth and ASP Advance ADx reimbursement and launch DecisionDx Melanoma growth
Revenue
$103.55M
▲ 20.1% YoY
Diluted EPS
$-0.07
▼ 146.7% YoY
Gross margin
77.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Castle Biosciences Inc (CSTL) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Castle Biosciences Inc (CSTL) Q1 2026 Earnings Call Transcript
Confident tone Revenue growth and guidance raise FDA submission timeline for melanoma test Advanced ADTx (atopic dermatitis) ramp
Revenue
$83.68M
▼ 4.9% YoY
Diluted EPS
$-0.49
Gross margin
75.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Transcript
Confident tone Financial performance and 2026 outlook TissueCypher growth in gastroenterology DecisionDx-Melanoma performance and adoption
Revenue
$87.01M*
▲ 0.8% YoY
Gross margin
79.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Castle Biosciences Inc (CSTL) Q3 2025 Earnings Call Transcript
Confident tone AdvanceAD-Tx launch in atopic dermatitis Q3 financial performance TissueCypher (Barrett's esophagus) growth
Revenue
$83.04M
▼ 3.2% YoY
Diluted EPS
$-0.02
▼ 125% YoY
Gross margin
77.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Castle Biosciences Inc (CSTL) Q2 2025 Earnings Call Transcript
Confident tone DecisionDx-SCC reimbursement and Novitas LCD Pipeline and M&A (SciBase and Previse) DecisionDx-Melanoma performance and growth
Revenue
$86.19M
▼ 0.9% YoY
Diluted EPS
$0.15
▼ 51.6% YoY
Gross margin
79.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Transcript
Confident tone Previse Acquisition / GI Pipeline Financial Performance DecisionDx-Melanoma
Revenue
$87.99M
▲ 20.6% YoY
Diluted EPS
$-0.90
Gross margin
81.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Transcript
Balanced tone DecisionDx-SCC reimbursement and Novitas LCD risk DecisionDx-Melanoma volume and penetration Balance sheet and financial strength
Revenue
$86.31M*
▲ 30.5% YoY
Gross margin
81.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Castle Biosciences Inc (CSTL) Q3 2024 Earnings Call Transcript
Confident tone Novitas Medicare Reimbursement Review for SCC DecisionDx-Melanoma Performance and Evidence DecisionDx-SCC Test Momentum
Revenue
$85.78M
▲ 39.5% YoY
Diluted EPS
$0.08
Gross margin
81.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Castle Biosciences Inc (CSTL) Q2 2024 Earnings Call Transcript
Confident tone DecisionDX-SCC growth and ART utility DecisionDX-Melanoma performance and clinical evidence Commercial payer coverage dynamics
Revenue
$87.00M
▲ 73.5% YoY
Diluted EPS
$0.31
Gross margin
83.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Castle Biosciences Inc (CSTL) Q1 2024 Earnings Call Transcript
Confident tone Clinical evidence and publications TissueCypher Barrett's esophagus test MolDX LCD process for SCC
Revenue
$72.97M
▲ 73.6% YoY
Diluted EPS
$-0.09
Gross margin
81.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Castle Biosciences Inc (CSTL) Q4 2023 Earnings Call Transcript
Confident tone Revenue and volume growth DecisionDx-SCC adoption and growth DecisionDx-melanoma clinical evidence
Revenue
$66.12M*
▲ 72.5% YoY
Gross margin
81.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Castle Biosciences Inc (CSTL) Q3 2023 Earnings Call Transcript
Revenue
$61.49M
▲ 66.1% YoY
Diluted EPS
$-0.26
Gross margin
81.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Castle Biosciences Inc (CSTL) Q2 2023 Earnings Call Transcript
Revenue
$50.14M
▲ 43.9% YoY
Diluted EPS
$-0.70
Gross margin
77.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Castle Biosciences Inc (CSTL) Q1 2023 Earnings Call Transcript
Revenue
$42.04M
▲ 56.6% YoY
Diluted EPS
$-1.10
Gross margin
75.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Castle Biosciences Inc (CSTL) Q4 2022 Earnings Call Transcript
Revenue
$38.34M*
▲ 53.1% YoY
Gross margin
75.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Castle Biosciences Inc (CSTL) Q3 2022 Earnings Call Transcript
Revenue
$37.01M
▲ 57.7% YoY
Diluted EPS
$-0.77
Gross margin
76.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Castle Biosciences Inc (CSTL) Q2 2022 Earnings Call Transcript
Revenue
$34.84M
▲ 53.1% YoY
Diluted EPS
$-0.06
Gross margin
77.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Castle Biosciences Inc (CSTL) Q1 2022 Earnings Call Transcript
Revenue
$26.85M
▲ 17.7% YoY
Diluted EPS
$-0.97
Gross margin
77.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Castle Biosciences Inc (CSTL) Q4 2021 Earnings Call Transcript
Revenue
$25.04M*
▲ 44.7% YoY
Gross margin
81.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Castle Biosciences Inc (CSTL) Q3 2021 Earnings Call Transcript
Revenue
$23.48M
▲ 54.3% YoY
Diluted EPS
$-0.47
Gross margin
80.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Castle Biosciences Inc (CSTL) Q2 2021 Earnings Call Transcript
Revenue
$22.76M
▲ 79% YoY
Diluted EPS
$-0.35
Gross margin
83.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Castle Biosciences Inc (CSTL) Q1 2021 Earnings Call Transcript
Revenue
$22.81M
▲ 31% YoY
Diluted EPS
$-0.17
▼ 666.7% YoY
Gross margin
86.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-08
Castle Biosciences Inc (CSTL) Q4 2020 Earnings Call Transcript
Revenue
$17.30M
▼ 1.9% YoY
Diluted EPS
$-0.23
▼ 309.1% YoY
Gross margin
84.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Castle Biosciences Inc (CSTL) Q3 2020 Earnings Call Transcript
Revenue
$15.22M
▲ 3% YoY
Diluted EPS
$-0.23
▼ 560% YoY
Gross margin
83.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Castle Biosciences Inc (CSTL) Q2 2020 Earnings Call Transcript
Revenue
$12.71M
▲ 18.4% YoY
Diluted EPS
$-0.08
Gross margin
83.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Castle Biosciences Inc (CSTL) Q1 2020 Earnings Call Transcript
Revenue
$17.42M
▲ 99.8% YoY
Diluted EPS
$0.03
Gross margin
86.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-09
Castle Biosciences Inc (CSTL) Q4 2019 Earnings Call
Revenue
$17.64M
▲ 54.2% YoY
Diluted EPS
$0.11
▼ 71.1% YoY
Gross margin
88.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–31 of 31 webcasts
Key facts CIK 1447362 CUSIP 14843C105 13F (30d) 30 filings 30 filers Visit website Investor relations